NM_058216.3:c.1097G>A
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.
The NM_058216.3(RAD51C):c.1097G>A(p.Arg366Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00000682 in 1,613,026 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_058216.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152050Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 249618Hom.: 0 AF XY: 0.00000742 AC XY: 1AN XY: 134818
GnomAD4 exome AF: 0.00000685 AC: 10AN: 1460858Hom.: 0 Cov.: 31 AF XY: 0.00000688 AC XY: 5AN XY: 726610
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152168Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74424
ClinVar
Submissions by phenotype
not provided Uncertain:2
The frequency of this variant in the general population, 0.000012 (3/249618 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant is described to be hypomorphic resulting in partial loss of function (PMID: 25292178 (2015), 22167183 (2012)). Additionally, the variant was reported in an individual with familial breast and/or ovarian cancer (PMID: 20400964 (2010)). Based on the available information, we are unable to determine the clinical significance of this variant. -
Observed in at least one family with breast cancer and segregated with disease in two affected relatives; however, tumor analysis from one individual demonstrated no loss of heterozygosity (Meindl et al., 2010; Gevensleben et al., 2014); Published functional studies demonstrate reduced homologous recombination activity compared to wild-type, increased sensitivity to PARP inhibitors, and moderate sensitivity to DNA damaging agents, but no significant difference in RAD51 foci formation or interaction with RAD51B, RAD51D, XRCC2, or XRCC3 (Meindl et al., 2010; Somyajit et al., 2012; Somyajit et al., 2015; Mishra et al., 2018; Prakash et al., 2022); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 25470109, 24993905, 25292178, 26740214, 20952512, 20400964, 14704354, 12966089, 36099300, 31567591, 29158291, 28829762, 34910513, 36562461, 22167183, 21537932) -
Hereditary cancer-predisposing syndrome Uncertain:2
The p.R366Q variant (also known as c.1097G>A), located in coding exon 9 of the RAD51C gene, results from a G to A substitution at nucleotide position 1097. The arginine at codon 366 is replaced by glutamine, an amino acid with highly similar properties. In a study of 1100 German high-risk breast and/or ovarian cancer families, this variant was detected in one family (Meindl A et al. Nat. Genet., 2010 May;42:410-4). Another study detected this variant in 1/492 breast cancer patients with family history of breast and/or ovarian cancer (Romero A et al. Breast Cancer Res. Treat., 2011 Oct;129:939-46). This variant was also identified in a cohort of individuals with at least 3 primary melanoma diagnoses (Li C et al. Melanoma Res, 2020 06;30:247-251). Functional studies have shown a reduction in homologous recombination activity from this alteration compared to wild-type protein (Somyajit K et al. Carcinogenesis, 2015 Jan;36:13-24). In another study, this alteration was shown to have reduced protein levels in the nucleus as compared to wild-type protein, but no change in protein levels in the mitochondria (Mishra A et al. Mol. Cell. Biol., 2018 02;38). However, in a homology-directed DNA repair (HDR) and PARP inhibitor and cisplatin sensitivity assay, this alteration showed a functionally normal read-out (Hu C et al. Cancer Res, 2023 Aug;83:2557-2571). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
This missense variant replaces arginine with glutamine at codon 366 of the RAD51C protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). Functional studies have reported conflicting findings for this variant for which some have reported hypomorphic or partial loss-of-function (PMID: 20400964, 22167183, 25292178), while others reported no impact on normal binding to RAD51 paralogs, sensitivity to cisplatin and Olaparib treatment and function in a homology-directed repair assay (PMID: 36099300, 37253112). This variant has been reported in several individuals affected with personal or family history of breast or ovarian cancer (PMID: 20400964, 23117857, 25470109). This variant also has been detected in a breast cancer case-control meta-analysis in 1/60466 cases and 2/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID RAD51C_000025). This variant has been identified in 3/249618 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
not specified Uncertain:1Benign:1
Curator: Arleen D. Auerbach. Submitter to LOVD: Johan den Dunnen. -
- -
Ovarian cancer Pathogenic:1
- -
Fanconi anemia complementation group O Uncertain:1
This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 366 of the RAD51C protein (p.Arg366Gln). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with breast cancer, ovarian cancer, and/or prostate cancer (PMID: 20400964, 35534704, 36099300). ClinVar contains an entry for this variant (Variation ID: 420041). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Experimental studies have shown that this missense change does not substantially affect RAD51C function (PMID: 36099300). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Breast-ovarian cancer, familial, susceptibility to, 3 Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at